Odyssey Therapeutics Inc (nasdaq:ODTX) Share Price

Company Profile

Business description
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
Contact
51 Sleeper Street
BostonMA02210
USA
T: +1 617 865-9628
https://www.odysseytx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees

Recommended

Real estate share remains cheap despite losing airport legal battle.

Yingqi Tan, CFA | 12 June 2026

The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.

Jacob Robbins | 11 June 2026

We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.

Seth Goldstein, CFA | 11 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,006.10	29.10	0.32%
CAC 40	8,314.07	113.28	1.38%
DAX 40	24,501.53	291.82	1.21%
Dow JONES (US)	51,017.00	168.25	0.33%
FTSE 100	10,436.01	132.13	1.28%
HKSE	24,718.10	468.81	1.93%
NASDAQ	25,683.13	126.53	-0.49%
Nikkei 225	66,020.04	1,802.77	2.81%
NZX 50 Index	13,393.87	191.71	1.45%
S&P 500	7,385.96	8.34	-0.11%
S&P/ASX 200	8,804.00	30.50	0.35%
SSE Composite Index	4,031.51	44.50	1.12%